United States· US:0023-6498_a4b2fc64-0045-4595-8194-98b7f2734d5e
UBRELVY
A ubrogepant product containing ubrogepant, registered in United States by Allergan, Inc.. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ubrogepant is registered in 2 of 19 countries.
Countries holding a registration under ATC N02CD04 (ubrogepant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Ubrogepant · ATC N02CD04
2 / 19 countries
- Canada
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- UBROGEPANT
- Manufacturer
- Allergan, Inc.
- Country
- United States (US)
- ATC code
- N02CD04
- ATC class
- Ubrogepant
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 5
- ndc110023-6498-01
- ndc110023-6498-04
- ndc110023-6498-10
- ndc110023-6498-16
- ndc110023-6498-30
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
118 interactions on record for ubrogepant.
Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ubrogepant · interactions on record
118 records
- 12 severe
- 106 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ubrogepant in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5dbc7693-cff7-4d92-87a8-86f3fb6619a2 GET /v1/drugs/5dbc7693-cff7-4d92-87a8-86f3fb6619a2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "UBROGEPANT",
"productndc": "0023-6498",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA211765",
"marketing_category": "NDA"
}See everything about ubrogepant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.